Together Mental Health Clinic is Now REMS Certified to Provide SPRAVATO® (esketamine) CIII Nasal Spray Medication for Adults with Treatment-Resistant Depression.

Get to know Spravato ®  

• Studied in adults with treatment-resistant depression
• Nasal spray you self-administer under the supervision of a healthcare provide
• Taken with an oral antidepressant
• Greater reduction of depression symptoms at four weeks‡ (compared to those who received a placebo and oral antidepressant)
• After 16 weeks of therapy, those patients who stayed on SPRAVATO®† did better than those who stopped therapy
• Tell your healthcare provider if you have a history of drug or alcohol abuse
• After you take SPRAVATO®, a healthcare provider will monitor you for at least two hours during the observation period for possible side effects. More About Side Effects

Spravato®  Safety  and Tolerability

• SPRAVATO® nasal spray was evaluated for safety in both short- and long-term clinical trials of adults diagnosed with treatment-resistant depression
• Do not take SPRAVATO® if you have a blood vessel disease (aneurysm), an abnormal connection between your blood vessels (arteriovenous malformation), a history of bleeding in the brain or are allergic to esketamine, ketamine or any of the ingredients in SPRAVATO®. Talk to your healthcare provider to learn more.